{"id":"methylprednisolone-and-ivig","safety":{"commonSideEffects":[{"rate":null,"effect":"Infection (opportunistic or bacterial)"},{"rate":null,"effect":"Hyperglycemia"},{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Infusion reactions"},{"rate":null,"effect":"Immunosuppression-related complications"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Methylprednisolone is a corticosteroid that reduces inflammatory cytokine production and immune cell activation. IVIG (intravenous immunoglobulin) modulates immune responses through multiple mechanisms including Fc receptor blockade, complement inhibition, and anti-inflammatory signaling. Together, this combination targets both innate and adaptive immune dysregulation.","oneSentence":"Methylprednisolone suppresses immune inflammation via glucocorticoid receptor signaling, while IVIG provides immunomodulation through Fc receptor engagement and anti-inflammatory pathways.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:21:10.546Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Autoimmune or inflammatory conditions in pediatric patients (specific indication context-dependent on trial design)"}]},"trialDetails":[{"nctId":"NCT07299695","phase":"PHASE3","title":"Intravenous Immunoglobulin for the Treatment of Acute Exacerbations of Idiopathic Pulmonary Fibrosis","status":"RECRUITING","sponsor":"Argyrios Tzouvelekis","startDate":"2026-01-25","conditions":"Idiopathic Pulmonary Fibrosis, Acute Exacerbation of Idiopathic Pulmonary Fibrosis","enrollment":196},{"nctId":"NCT07410039","phase":"PHASE4","title":"Therapy in the Acute Phase of NMOSD: A Multicenter Prospective Real-World Study","status":"RECRUITING","sponsor":"Chinese PLA General Hospital","startDate":"2026-02-01","conditions":"Neuromyelitis Optica Spectrum Disorder Attack","enrollment":200},{"nctId":"NCT04438382","phase":"PHASE2","title":"Infliximab and Intravenous Immunoglobulin Therapy in Treating Patients With Steroid-Refractory Pneumonitis","status":"TERMINATED","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2021-01-07","conditions":"Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Steroid-Refractory Pneumonitis","enrollment":1},{"nctId":"NCT03286556","phase":"PHASE2","title":"Autoantibody Reduction for Acute Exacerbations of Idiopathic Pulmonary Fibrosis","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2018-09-04","conditions":"Idiopathic Pulmonary Fibrosis, Acute Fatal Form","enrollment":82},{"nctId":"NCT04224558","phase":"PHASE1, PHASE2","title":"Stem Cell Transplantation in Crohn's Disease","status":"RECRUITING","sponsor":"Cedars-Sinai Medical Center","startDate":"2019-11-15","conditions":"Crohn Disease","enrollment":15},{"nctId":"NCT03292861","phase":"PHASE2","title":"The Effect and Safety Profile of Thymoglobulin® in Primary Cardiac Transplant Recipients","status":"ENROLLING_BY_INVITATION","sponsor":"Cedars-Sinai Medical Center","startDate":"2018-09-13","conditions":"Heart Transplantation","enrollment":60},{"nctId":"NCT04078568","phase":"PHASE3","title":"Efficacy of Immunoglobulin Plus Prednisolone in Reducing Coronary Artery Lesion in Patients With Kawasaki Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Hospital of Fudan University","startDate":"2020-01-15","conditions":"Kawasaki Disease","enrollment":3208},{"nctId":"NCT04701034","phase":"PHASE2","title":"Intravenous Immunoglobulin and Prednisolone for RPL After ART.","status":"COMPLETED","sponsor":"Aalborg University Hospital","startDate":"2021-01-28","conditions":"Habitual Abortion, Recurrent Pregnancy Loss, Fertility Disorders","enrollment":80},{"nctId":"NCT03939637","phase":"PHASE3","title":"Eltrombopag vs Standard Front Line Management for Newly Diagnosed Immune Thrombocytopenia (ITP) in Children","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2019-05-02","conditions":"Immune Thrombocytopenia","enrollment":122},{"nctId":"NCT04372615","phase":"PHASE2","title":"The ExTINGUISH Trial of Inebilizumab in NMDAR Encephalitis","status":"RECRUITING","sponsor":"University of Utah","startDate":"2022-03-30","conditions":"Autoimmune Encephalitis, Encephalitis","enrollment":116},{"nctId":"NCT03542279","phase":"NA","title":"CPI Combination Therapy for Autoimmune Encephalitis","status":"COMPLETED","sponsor":"Xuanwu Hospital, Beijing","startDate":"2020-11-25","conditions":"Autoimmune Encephalitis","enrollment":70},{"nctId":"NCT02205762","phase":"PHASE2, PHASE3","title":"LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis","status":"RECRUITING","sponsor":"North American Consortium for Histiocytosis","startDate":"2016-11-02","conditions":"Langerhans Cell Histiocytosis","enrollment":1400},{"nctId":"NCT03994783","phase":"PHASE3","title":"Transplant Antibody-Mediated Rejection: Guiding Effective Treatments","status":"TERMINATED","sponsor":"Imperial College London","startDate":"2019-07-17","conditions":"Kidney Transplant Rejection, Antibody-mediated Rejection","enrollment":3},{"nctId":"NCT03194815","phase":"PHASE2","title":"IVIG and Rituximab in Antibody-associated Psychosis - SINAPPS2","status":"RECRUITING","sponsor":"University of Cambridge","startDate":"2017-11-01","conditions":"Psychosis, Autoimmune Encephalitis","enrollment":70},{"nctId":"NCT06896253","phase":"PHASE2","title":"Pulse Corticosteroids Or/and Immunoglobulins to Treat Fulminant Myocarditis","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2025-04","conditions":"Myocarditis Acute","enrollment":120},{"nctId":"NCT03647852","phase":"NA","title":"Clinical Study on Strategy for Refractory Henoch-Schönlein Purpura","status":"RECRUITING","sponsor":"Children's Hospital of Fudan University","startDate":"2019-09-01","conditions":"Henoch-Schönlein Purpura","enrollment":150},{"nctId":"NCT06373211","phase":"PHASE2","title":"Early Immunotherapy with Intravenous Immunoglobulin, Cyclophosphamide and Methylprednisolone in Patients with Anti-Hu-associated Paraneoplastic Sensory Neuronopathy","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2025-01-10","conditions":"Paraneoplastic Sensory Neuronopathy","enrollment":21},{"nctId":"NCT04826588","phase":"PHASE3","title":"Randomised Evaluation of COVID-19 Therapy (RECOVERY) in Children With PIMS-TS in Switzerland (SWISSPED-RECOVERY)","status":"COMPLETED","sponsor":"University Children's Hospital Basel","startDate":"2021-05-23","conditions":"Paediatric Inflammatory Multisystem Syndrome-Temporally Associated With SARS-CoV-2 (PIMS-TS)","enrollment":76},{"nctId":"NCT03289403","phase":"PHASE2","title":"The Role of Immunomodulatory Treatment in Success of ICSI in Patients With Autoimmune Thyroiditis","status":"COMPLETED","sponsor":"Aljazeera Hospital","startDate":"2018-03-07","conditions":"Infertility, Autoimmune Thyroiditis","enrollment":194},{"nctId":"NCT06696807","phase":"","title":"Immunomodulatory Therapy & VSA","status":"COMPLETED","sponsor":"Dao Wen Wang","startDate":"2018-10-01","conditions":"Vasospastic Angina","enrollment":71},{"nctId":"NCT06223984","phase":"PHASE4","title":"Combined Use of Immunoglobulin and Pulse Steroid Therapies in Severe Covid-19 Patients","status":"COMPLETED","sponsor":"Konya City Hospital","startDate":"2020-03-30","conditions":"Pulse Steroid and Immunoglobulins Drugs in Covid 19 Patients","enrollment":178},{"nctId":"NCT04381936","phase":"PHASE3","title":"Randomised Evaluation of COVID-19 Therapy","status":"RECRUITING","sponsor":"University of Oxford","startDate":"2020-03-19","conditions":"Severe Acute Respiratory Syndrome","enrollment":70000},{"nctId":"NCT06041451","phase":"PHASE4","title":"Early and Late Prognosis in Patients With Guillain-Barre Syndrome","status":"UNKNOWN","sponsor":"First Affiliated Hospital of Wenzhou Medical University","startDate":"2013-01-02","conditions":"Guillain-Barre Syndrome","enrollment":450},{"nctId":"NCT05604859","phase":"PHASE4","title":"Evaluate the Efficacy and Safety of Various Treatment Schemes for Severe Fever With Thrombocytopenia Syndrome(SFTS)","status":"UNKNOWN","sponsor":"Qin Ning","startDate":"2022-08-19","conditions":"Severe Fever With Thrombocytopenia Syndrome","enrollment":350},{"nctId":"NCT05177939","phase":"PHASE3","title":"Phase III Clinical Study of NPB-01 in Patients With Autoimmune Encephalitis","status":"UNKNOWN","sponsor":"Nihon Pharmaceutical Co., Ltd","startDate":"2022-03-03","conditions":"Autoimmune Encephalitis","enrollment":40},{"nctId":"NCT03412188","phase":"NA","title":"The Effect of Eltrombopag on the Expression of Platelet Collagen Receptor GPVI in Pediatric ITP.","status":"COMPLETED","sponsor":"Nayera Hazaa Elsherif","startDate":"2018-08-01","conditions":"Idiopathic Thrombocytopenic Purpura","enrollment":36},{"nctId":"NCT04101578","phase":"","title":"Clinical Prognosis and Progression of Myasthenia Gravis Patients","status":"UNKNOWN","sponsor":"Da, Yuwei, M.D.","startDate":"2017-02-08","conditions":"Myasthenia Gravis","enrollment":2000},{"nctId":"NCT04411667","phase":"PHASE4","title":"Study of SOC Plus IVIG Compared to SOC Alone in the Treatment of COVID-19","status":"COMPLETED","sponsor":"George Sakoulas, MD","startDate":"2020-04-28","conditions":"Sars-CoV2","enrollment":34},{"nctId":"NCT03342638","phase":"PHASE3","title":"Maximizing Outcome of Multiple Sclerosis Transplantation","status":"TERMINATED","sponsor":"Northwestern University","startDate":"2017-11-08","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":66},{"nctId":"NCT03593902","phase":"PHASE2, PHASE3","title":"Cardiac Safe Transplants for Systemic Sclerosis","status":"TERMINATED","sponsor":"Northwestern University","startDate":"2018-05-17","conditions":"Systemic Sclerosis, Scleroderma","enrollment":9},{"nctId":"NCT03584802","phase":"NA","title":"Therapeutic Plasma Exchange, Rituximab and IV Ig for Severe Acute Exacerbation of IPF Admitted in ICU","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2019-05-16","conditions":"Exacerbation of Idiopathic Pulmonary Fibrosis","enrollment":40},{"nctId":"NCT03829566","phase":"PHASE2, PHASE3","title":"Autologous Transplant To End NMO Spectrum Disorder","status":"WITHDRAWN","sponsor":"Northwestern University","startDate":"2019-11","conditions":"Neuromyelitis Optica, Devic's Disease, NMO Spectrum Disorder","enrollment":""},{"nctId":"NCT01093586","phase":"PHASE2","title":"Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies","status":"COMPLETED","sponsor":"Case Comprehensive Cancer Center","startDate":"2007-09","conditions":"Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Megakaryoblastic Leukemia (M7)","enrollment":14},{"nctId":"NCT03530462","phase":"","title":"To Explore Cognitive Neural Mechanism of Autoimmune Encephalitis by Using Neuropsychological Tests and Multi-modal MRI","status":"COMPLETED","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2017-04-07","conditions":"Cognitive Impairment, Autoimmune Encephalitis","enrollment":22},{"nctId":"NCT02439996","phase":"PHASE3","title":"Different Doses of IVIG for Kawasaki Disease","status":"COMPLETED","sponsor":"Children's Hospital of Fudan University","startDate":"2014-01","conditions":"Kawasaki Disease","enrollment":404},{"nctId":"NCT03200561","phase":"PHASE3","title":"A Trial to Evaluate the Efficacy of Immunoglobulin Plus Steroid for Prevention of Coronary Artery Abnormalities in Taiwanese Refractory Kawasaki Disease (RAST Study)","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2013-10-17","conditions":"Kawasaki Disease, Steroid, Immuoglobulin","enrollment":100},{"nctId":"NCT02398994","phase":"PHASE3","title":"A Multicentre randomiSed Controlled TRial of IntraVEnous Immunoglobulin Versus Standard Therapy for Transverse Myelitis","status":"TERMINATED","sponsor":"Guy's and St Thomas' NHS Foundation Trust","startDate":"2015-03","conditions":"Myelitis, Transverse, Neuromyelitis Optica","enrollment":2},{"nctId":"NCT00376077","phase":"PHASE3","title":"A Randomized Study of IVIG vs. IVIG With High Dose Methylprednisolone in Childhood ITP.","status":"COMPLETED","sponsor":"The Hospital for Sick Children","startDate":"2005-08","conditions":"Immune Thrombocytopenic Purpura","enrollment":32},{"nctId":"NCT02695797","phase":"PHASE4","title":"Immunotherapy in Intractable Cryptogenic Epilepsy Patients With Autoimmune Antibody","status":"UNKNOWN","sponsor":"Seoul National University Hospital","startDate":"2015-09","conditions":"Epilepsy, Unspecified, Intractable","enrollment":40},{"nctId":"NCT00230035","phase":"PHASE2","title":"Lupus Immunosuppressive/Immunomodulatory Therapy or Stem Cell Transplant (LIST)","status":"WITHDRAWN","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2005-09","conditions":"Systemic Lupus Erythematosus","enrollment":""},{"nctId":"NCT01763658","phase":"PHASE2, PHASE3","title":"Oxidant Status and Effect of Antioxidant in Immune Thrombocytopenia","status":"UNKNOWN","sponsor":"Ain Shams University","startDate":"2013-03","conditions":"Immune Thrombocytopenia","enrollment":100},{"nctId":"NCT01554930","phase":"NA","title":"Effectiveness and Safety of Chinese Medicine to Treat Hand, Foot, and Mouth Disease","status":"COMPLETED","sponsor":"Jiangxi Qingfeng Pharmaceutical Co. Ltd.","startDate":"2010-05","conditions":"Hand, Foot, and Mouth Disease","enrollment":230}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Solumedrol"],"phase":"phase_3","status":"active","brandName":"Methylprednisolone and IVIG","genericName":"Methylprednisolone and IVIG","companyName":"The Hospital for Sick Children","companyId":"the-hospital-for-sick-children","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Methylprednisolone suppresses immune inflammation via glucocorticoid receptor signaling, while IVIG provides immunomodulation through Fc receptor engagement and anti-inflammatory pathways. Used for Autoimmune or inflammatory conditions in pediatric patients (specific indication context-dependent on trial design).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}